Please Note: This trial is no longer enrolling new participants
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
| Protocol No. | CTO-NRG-HN014 | Scope | National |
|---|---|---|---|
| Principal Investigator | Janice Farlow | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
